- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Autolus Therapeutics Ltd (AUTL)
Autolus Therapeutics Ltd stock price live, this page displays NASDAQ AUTL stock exchange data. View the AUTL premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Autolus Therapeutics Ltd real time stock price chart below.
What Is the Autolus Therapeutics Ltd Stock Price Today?
The Autolus Therapeutics Ltd stock price today is 2.150.
What Is the Stock Symbol for Autolus Therapeutics Ltd?
The stock symbol for Autolus Therapeutics Ltd is "AUTL."
What Stock Exchange Does Autolus Therapeutics Ltd Trade On?
Autolus Therapeutics Ltd is listed and trades on the NASDAQ stock exchange.
Is Autolus Therapeutics Ltd a Good Stock to Buy?
Determining whether Autolus Therapeutics Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AUTL quote. (ISIN: US05280R1005)
What Is the Autolus Therapeutics Ltd Stock Price Today?
The Autolus Therapeutics Ltd stock price today is 2.150.
What Is the Stock Symbol for Autolus Therapeutics Ltd?
The stock symbol for Autolus Therapeutics Ltd is "AUTL."
What Stock Exchange Does Autolus Therapeutics Ltd Trade On?
Autolus Therapeutics Ltd is listed and trades on the NASDAQ stock exchange.
Is Autolus Therapeutics Ltd a Good Stock to Buy?
Determining whether Autolus Therapeutics Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AUTL quote. (ISIN: US05280R1005)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.040
2.240
52 wk Range
1.175
2.430
AUTL is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.0402.240
52 wk Range
1.1752.430
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AUTL Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
8.725
Upside
+305.81%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Strong Buy
Analyst Ratings
9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 8.725
(+305.81% Upside)
Autolus Therapeutics Ltd Earnings Call Summary for Q2/2026
- Q2 revenue of $45.7M beat estimates by 52%, up 74% sequentially and 119% YoY; EPS loss of $0.15 beat forecast of $0.23 loss.
- Gross margin surged to 55% from 6% in Q1, targeting 65-70% within 12-18 months driven by manufacturing efficiency and higher volumes.
- Raised 2026 revenue guidance to $140M-$150M from $120M-$135M; secured $250M credit facility extending cash runway into Q2 2028.
- Expanded U.S. treatment centers to 80+, targeting 90+ by year-end; AUCATZYL adoption accelerating via positive real-world evidence.
- Pipeline milestones include lupus and amyloidosis data by end-2026, MS data in 2027, and pediatric ALL data by end-2027.
Last Updated: 2026-08-11, 09:34 a/m
Read Full TranscriptEarnings
Latest Release
Aug 11, 2026
EPS / Forecast
-0.15 / -0.23
Revenue / Forecast
45.69M / 30.08M
Compare AUTL to Peers and Sector
Metrics to compare | AUTL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAUTLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.0x | −4.3x | −0.4x | |
PEG Ratio | 0.10 | −0.07 | 0.00 | |
Price/Book | 5.3x | 1.7x | 2.6x | |
Price / LTM Sales | 4.9x | 16.9x | 3.1x | |
Upside (Analyst Target) | 349.2% | 143.6% | 47.8% | |
Fair Value Upside | Unlock | 11.0% | 6.2% | Unlock |
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Autolus Therapeutics (AUTL) Stock Price Today?
The Autolus Therapeutics stock price today is 2.150 USD.
What Stock Exchange Does Autolus Therapeutics Trade On?
Autolus Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Autolus Therapeutics?
The stock symbol for Autolus Therapeutics is "AUTL."
What Is the Autolus Therapeutics Market Cap?
As of today, Autolus Therapeutics market cap is 590.840M USD.
What Is Autolus Therapeutics's Earnings Per Share (TTM)?
The Autolus Therapeutics EPS (TTM) is -1.053.
When Is the Next Autolus Therapeutics Earnings Date?
Autolus Therapeutics will release its next earnings report on Oct 29, 2026.
From a Technical Analysis Perspective, Is AUTL a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Autolus Therapeutics Stock Split?
Autolus Therapeutics has split 0 times.
How Many Employees Does Autolus Therapeutics Have?
Autolus Therapeutics has 753 employees.
What is the current trading status of Autolus Therapeutics (AUTL)?
As of Aug 15, 2026, Autolus Therapeutics (AUTL) is trading at a price of 2.150 USD, with a previous close of 2.220 USD. The stock has fluctuated within a day range of 2.040 USD to 2.240 USD, while its 52-week range spans from 1.175 USD to 2.430 USD.
What Is Autolus Therapeutics (AUTL) Price Target According to Analysts?
The average 12-month price target for Autolus Therapeutics is 8.725 USD, with a high estimate of 11 USD and a low estimate of 5 USD. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +305.81% Upside potential.
What Is the AUTL Premarket Price?
AUTL's last pre-market stock price is 2.200 USD. The pre-market share volume is 4,930.000, and the stock has decreased by -0.020, or -0.900%.
What Is the AUTL After Hours Price?
AUTL's last after hours stock price is 2.165 USD, the stock has decreased by 0.015, or 0.680%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.